Thông tin thuốc gốc
Chỉ định và Liều dùng
Chronic heart failure
Adult: In stable chronic heart failure with reduced systolic left ventricular function as an adjunct to ACE inhibitors, diuretics, and optionally cardiac glycosides: Initially, 1.25 mg once daily for 1 week. If tolerated, increase gradually as follows: 2.5 mg once daily for a further week, 3.75 mg once daily for a further week, 5 mg once daily for the 4 following weeks, 7.5 mg once daily for the 4 following weeks, then 10 mg once daily for maintenance. Max: 10 mg once daily. Gradual dose reduction may be considered if the Max recommended dose is not well tolerated. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).

Angina pectoris, Hypertension
Adult: Initially, 5 mg once daily. Usual maintenance dose: 10 mg once daily. Max: 20 mg daily. Adjust dose according to individual requirements.
Nhóm bệnh nhân đặc biệt
Patients with bronchospastic disease: Initially, 2.5 mg once daily.
Suy thận
Angina pectoris; Hypertension:
CrCl (mL/min) Dosage
<40 Initially, 2.5 mg once daily. Max: 10 mg once daily.
Suy gan
Angina pectoris; Hypertension:
Initially, 2.5 mg once daily. Max: 10 mg once daily.
Cách dùng
May be taken with or without food.
Chống chỉ định
Acute heart failure or during episodes of heart failure decompensation requiring IV inotropic therapy; symptomatic bradycardia; cardiogenic shock, 2nd- and 3rd-degree atrioventricular block (without pacemaker), sinoatrial block, severe bronchial asthma or COPD; sick sinus syndrome, symptomatic hypotension; severe peripheral arterial occlusive disease, severe Raynaud's syndrome; metabolic acidosis, untreated phaeochromocytoma.
Thận trọng
Patient with ischaemic heart disease, 1st-degree atrioventricular block, bronchospastic disease, diabetes mellitus with large fluctuations in blood glucose levels; peripheral arterial occlusive disease, Prinzmetal's angina, phaeochromocytoma, psoriasis or history of psoriasis; thyrotoxicosis, myasthenia gravis, history of anaphylactic reaction to allergens. Patients undergoing surgery involving general anaesthesia; ongoing desensitisation therapy or strict fasting. Avoid abrupt withdrawal. May mask the signs and symptoms of hypoglycaemia and hyperthyroidism (particularly tachycardia). Renal (CrCl <40 mL/min) and hepatic impairment. Pregnancy and lactation.
Tác dụng không mong muốn
Cardiac disorders: Bradycardia, worsening of pre-existing heart failure (in patients with chronic heart failure).
Gastrointestinal disorders: Nausea, vomiting, constipation, diarrhoea.
General disorders and administration site conditions: Fatigue, asthenia.
Nervous system disorders: Headache, dizziness.
Vascular disorders: Feeling of coldness or numbness in the extremities, hypotension.
Chỉ số theo dõi
Monitor blood pressure, heart rate, ECG; serum glucose (in diabetic patients); symptoms of bronchospasm (in patients with pre-existing bronchospastic disease) and worsening heart failure during the titration phase.
Quá liều
Symptoms: Bradycardia, bronchospasm, hypotension, acute cardiac insufficiency, hypoglycaemia. Management: Supportive and symptomatic treatment. The following may be administered to treat symptoms: IV atropine for bradycardia (isoprenaline or another agent with positive chronotropic properties may be given if the response is insufficient; transvenous pacemaker insertion may be considered if necessary); IV fluids and vasopressors for hypotension (IV glucagon may also be useful); isoprenaline for 2nd- or 3rd-degree atrioventricular block (may consider transvenous cardiac pacemaker insertion); IV diuretics, inotropic agents or vasodilating agents for acute worsening of heart failure; bronchodilator therapy (e.g. isoprenaline, β2-sympathomimetic drugs and/or aminophylline) for bronchospasm; IV glucose for hypoglycaemia.
Tương tác
Concomitant use with Ca antagonist (e.g. verapamil, diltiazem) may lead to reduced contractility of the heart muscle and delayed atrioventricular impulse conduction. Concomitant use of centrally acting antihypertensive drugs (e.g. clonidine, methyldopa, moxonidine, rilmenidine) may further decrease the central sympathetic tonus (reduction of heart rate and cardiac output, vasodilation). Effect on atrioventricular conduction time may be potentiated with Class I (e.g. disopyramide, quinidine) and Class III (e.g. amiodarone) antidysrhythmic agents. May increase atrioventricular conduction time and the risk of bradycardia with parasympathomimetic drugs. May intensify the blood sugar-lowering effects of insulin and oral antidiabetic agents. Reduced heart rate and increased atrioventricular conduction time with digitalis glycosides. May attenuate reflex tachycardia and increase the risk of hypotension with anaesthetic drugs. NSAIDs may reduce the hypotensive effect of bisoprolol. Concomitant use of β-sympathomimetic agents (e.g. isoprenaline, dobutamine) and bisoprolol may reduce the effect of both agents. May unmask the α-adrenoceptor-mediated vasoconstrictor effects of sympathomimetics that activate both β- and α-adrenoceptors (e.g. norepinephrine, epinephrine) leading to increased blood pressure and exacerbated intermittent claudication. Increase risks of hypotension with other antihypertensive agents (e.g. dihydropyridine Ca antagonists) and other drugs with blood pressure lowering potential (e.g. TCAs, barbiturates, phenothiazines). Increased risk of bradycardia with mefloquine. Enhanced hypotensive effect and risk for hypertensive crisis with MAOIs (except MAO-B inhibitors). Reduced elimination half-life with rifampicin. May produce an excessive reduction of sympathetic activity with catecholamine-depleting drugs (e.g. reserpine, guanethidine). Topical β-blockers (e.g. eye drops for glaucoma treatment) may add to the systemic effects of bisoprolol. Concurrent use with moxisylyte may cause severe postural hypotension.
Ảnh hưởng đến kết quả xét nghiệm
May cause a false-positive aldosterone/renin ratio.
Tác dụng
Mechanism of Action: Bisoprolol is a potent and highly selective β1-adrenoreceptor blocking agent with little or no effect on β2-receptors of the bronchial and vascular smooth muscle except at high doses (≥20 mg). Its mechanism of action in the treatment of hypertension is not fully established but may be associated with reduction of cardiac output, inhibition of renin release by the kidneys, and diminution of sympathetic outflow from the vasomotor centres in the brain. In the treatment of angina, the blockade of β1-receptors reduces heart action thereby reducing oxygen demand.
Onset: 1-2 hours.
Absorption: Rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability: Approx 90%. Time to peak plasma concentration: 2-4 hours.
Distribution: Widely distributed in the body with high concentrations in the heart, liver, lungs, and saliva. Crosses the blood-brain barrier. Volume of distribution: 3.5 L/kg. Plasma protein binding: Approx 30%.
Metabolism: Extensively metabolised in the liver to inactive metabolites; undergoes significant first-pass metabolism (approx 20%).
Excretion: Via urine (50% as unchanged drug; remainder as inactive metabolites); faeces (<2%). Elimination half-life: 9-12 hours.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 2405, Bisoprolol. Accessed June 28, 2022.

Bảo quản
Store between 20-25°C. Protect from moisture.
Phân loại MIMS
Thuốc chống đau thắt ngực / Thuốc chẹn thụ thể bêta
Phân loại ATC
C07AB07 - bisoprolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Tài liệu tham khảo
Anon. Bisoprolol Fumarate. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 17/05/2022.

Anon. Bisoprolol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 17/05/2022.

Bisoprolol Fumarate 10 mg Tablets (Healthcare Pharma Limited). MHRA. Accessed 17/05/2022.

Bisoprolol Fumarate 5 mg Film-coated Tablets (Flamingo Pharma UK Ltd). MHRA. Accessed 17/05/2022.

Bisoprolol Fumarate Tablet, Film Coated (TruPharma, LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 17/05/2022.

Buckingham R (ed). Bisoprolol Fumarate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 17/05/2022.

Cardicor 1.25 mg Film-coated Tablets (Merck Serono Limited). MHRA. Accessed 17/05/2022.

Concor 10 mg Film Coated Tablet (Merck Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 21/06/2022.

Douglas Pharmaceuticals Ltd. Bosvate 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, 10 mg Tablet data sheet 7 September 2018. Medsafe. Accessed 17/05/2022.

Joint Formulary Committee. Bisoprolol Fumarate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 17/05/2022.

Vasoten F.C. Tablets 5 mg (Apex Pharmacy Marketing Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 17/05/2022.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Bisoprolol từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Agicardi
  • Bio-Biso 5
  • Biprolol
  • Biscapro 2.5/5
  • Biselect
  • Bisoblock
  • Bisohexal
  • Bisolcor
  • Bisoprolol Fumarate Actavis
  • Bisoprolol OPV
  • Bisostad
  • Bisotab
  • Cardicormekophar
  • Concor
  • Concor COR
  • Domecor
  • Glocor
  • Haiblok
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in